INTRODUCTION
============

Ursolic acid (UA) and its isomer oleanolic acid (OA) are pentacyclic triterpenoids that are common in the plant kingdom. They have similar structures ([Fig. 1](#f1-bt-22-3-254){ref-type="fig"}) and share distributional similarity in the natural world, often occurring together ([@b19-bt-22-3-254]; [@b26-bt-22-3-254]), especially in important medicinal plants such as Fructus *Ligustrum lucidum* ([@b35-bt-22-3-254]; [@b37-bt-22-3-254]) and Fructus *Forsythiae* ([@b37-bt-22-3-254]) used in traditional East Asian medicine, and *Ocimum sanctum* Linn (Holy Basil) used in Ayurvedic medicine ([@b29-bt-22-3-254]). UA and OA are also abundant in food seasonings, such as rosemary ([@b10-bt-22-3-254]), sage ([@b7-bt-22-3-254]), and olive oil ([@b3-bt-22-3-254]). Hence, people can be readily exposed to UA and OA naturally or intentionally.

The similarity of UA and OA includes various biological activities ([@b19-bt-22-3-254]; [@b26-bt-22-3-254]). Initially, a hepatoprotective effect was identified for them. Diverse pharmacological activities reported since include anti-inflammatory, antioxidant, anticancer, and antimicrobial effects ([@b19-bt-22-3-254], [@b20-bt-22-3-254]; [@b8-bt-22-3-254]). Despite their benefits, UA and OA have some detrimental characteristics. UA exhibits anti-inflammatory effect in cells with established inflammation, but can be pro-inflammatory in normal cells ([@b8-bt-22-3-254]). Similarly, OA is hepatoprotective at low doses, but it can induce cholestasis and hepatotoxicity at high doses ([@b20-bt-22-3-254]).

Both UA and OA possess cardiovascular protective effects. They are effective against chemically-induced dysrhythmia ([@b30-bt-22-3-254]) and protect cardiac cells from ischemic damage in a rat model of myocardial ischemia ([@b34-bt-22-3-254]; [@b27-bt-22-3-254]). They exhibit vasorelaxant activity in isolated blood vessels ([@b1-bt-22-3-254]; [@b28-bt-22-3-254]) and are capable of reducing blood pressure in hypertension animal models ([@b31-bt-22-3-254]). However, recent studies involving the circulatory system have been more equivocal. UA reportedly accelerates atherosclerotic plaque formation *in vivo* ([@b22-bt-22-3-254]), contrary to another study showing the protective effect of UA against diabetes-accelerated atherosclerosis ([@b33-bt-22-3-254]). OA directly elicits aggregation of isolated platelets ([@b21-bt-22-3-254]), a process that is critically involved in the initiation of cardiovascular events ([@b21-bt-22-3-254]), although other studies addressed the antiplatelet effect of UA and OA and anticoagulant activity of OA ([@b14-bt-22-3-254]; [@b15-bt-22-3-254]; [@b4-bt-22-3-254]). These inconsistent reports therefore prompted the present study.

Platelet aggregation is crucial in hemostasis under normal physiological conditions. Abnormal activation or hyperaggregation of platelets caused by xenobiotics including drugs, food and environmental toxicants, readily leads to thrombosis. Such altered platelet function is involved in the pathogenesis of atherosclerosis and inflammation, which ultimately contributes to the development of acute coronary syndrome (ACS), stroke, and the ischemic complications of peripheral vascular disease. Therefore, xenobiotics enhancing platelet activity are regarded as risk factors for cardiovascular diseases, and anti-platelet therapy is a general approach to prevent and manage them ([@b21-bt-22-3-254]).

In the present study, the biological activity of UA and OA was examined in an isolated platelet system to clarify their effects on platelet function.

MATERIALS AND METHODS
=====================

Reagents
--------

UA and OA were purchased from Abcam (Cambridge, UK). Adenosine diphosphate (ADP) and collagen were from Chrono-log (Havertown, PA, USA). Thrombin, sodium pyruvate, β-nicotinamide adenine dinucleotide reduced disodium salt hydrate (NADH), menadione and dipyridamole were obtained from Sigma-Aldrich (St. Louis, MO, USA). Hematologic reagents for prothrombin time (PT) and activated thromboplastin time (aPTT) assays were purchased from Fisher Diagnostics (Middletown, VA, USA). Heparin was obtained from Choongwae Pharma (Seoul, Korea). All other chemicals used were of the highest purity available and were purchased from standard suppliers.

Animals
-------

All animal experiments were conducted in accordance with protocols approved by the Ethics Committee of Animal Service Center, Dongguk University. Male Sprague-Dawley rats (6--7 weeks of age) purchased from Daehan Biolink (Eumseong, Korea) were acclimated for 1 week before experiments. The laboratory animal facility was maintained at a constant temperature and humidity with a 12-h light/dark cycle. Food and water were provided *ad libitum*.

Preparation of washed platelets
-------------------------------

Washed platelets (WP) were prepared as described previously ([@b21-bt-22-3-254]). Briefly, blood was collected from the abdominal aorta of rats anesthetized with ether using acid-citrate-dextrose (ACD; 85 mM trisodium citrate, 66.6 mM citric acid, and 111 mM glucose) as an anticoagulant (ACD: blood =1:6). After centrifugation at 250×*g* for 15 min, platelet-rich plasma (PRP) was obtained from the supernatant. Platelets were centrifuged at 500×*g* for 10 min, and washed once with a buffer comprised of 138 mM NaCl, 2.8 mM KCl, 0.8 mM MgCl~2~, 0.8 mM NaH~2~PO~4~, 10 mM HEPES, and 5 mM EDTA (pH 7.4) by suspension and centrifugation. WP were prepared by resuspending the platelet pellets in suspension buffer solution (138 mM NaCl, 2.8 mM KCl, 0.8 mM MgCl~2~, 0.8 mM NaH~2~PO~4~, 10 mM HEPES, 5.6 mM dextrose, and 1mM CaCl~2~, pH 7.4). The number of cells was adjusted to 2×10^8^ cells/ml.

Platelet aggregation
--------------------

Platelet aggregation experiments were performed using a four-channel aggregometer (Chrono-log) as described previously ([@b21-bt-22-3-254]). WP were treated with the indicated concentrations of UA or OA for 5 min, and were stimulated with either thrombin, ADP, or collagen. Aggregation was assessed by measuring the changes in light transmission with the aggregometer.

Whole blood aggregation
-----------------------

Blood was collected from the abdominal aorta of ether-anesthetized rats using 3.2% sodium citrate as an anticoagulant (sodium citrate:blood=1:9) and diluted with normal saline (1:1). Blood was incubated with UA or OA for 5 min and was stimulated with thrombin. Aggregation was assessed by measuring the impedance change with a whole blood aggregometer (Chrono-log).

Plasma coagulation
------------------

Plasma coagulability was tested by measuring prothrombin time (PT) and activated partial thromboplastin time (aPTT) using a Coagulator2 analyzer (Behnk Elektronik, Norderstedt, Germany) with thromboplastin-D or CaCl~2~ and APTT-XL re-agents (Fisher Diagnostics) respectively, according to the manufacturer's instructions.

Lactate dehydrogenase (LDH) release assay
-----------------------------------------

Cytotoxicity of UA and OA were evaluated by LDH release assay as previously described ([@b25-bt-22-3-254]). WP were treated with 50 μM UA or OA, or 250 μM menadione, a positive control, and centrifuged at 13,000 *g* for 1 min. Resultant supernatant was used for LDH activity assay. Supernatant 20 μl was added to a 200 μl aliquot of working reagent containing 0.2 mM NADH and 2.5 mM sodium pyruvate in wells of 96-well plates. The decrease in absorbance at 340 nm was measured for 3 min with a SpectraMax M3 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Relative LDH activity was calculated from the slope of decreasing absorbance. LDH activities measured from 1% Triton X-100-treated WP were regarded as 100% release.

Statistical analyses
--------------------

The mean and standard error (SE) of the mean were calculated for all experimental groups. The data were subjected to one-way analysis of variance (ANOVA) or the Kruskal-Wallis test followed by Bonferroni correction to determine significant differences from the control. Statistical analyses were performed using SigmaStat Version 3.5 (Systat Software, San Jose, CA). In all cases, *p*\<0.05 indicated significance.

RESULTS
=======

To test the effects of UA and OA on platelet aggregation, aggregatory responses to platelet agonists were assessed in UA-or OA-exposed WP. UA and OA were confirmed not to change platelet shape on an aggregometer, suggesting that they do not aggregate platelets directly (data not shown). Platelets were incubated with 5, 25, or 50 μM UA for 5 min and aggregation was elicited by the addition of 0.06--0.08 U/ml thrombin, which is a concentration that induced an intermediate extent of aggregation determined using an aggregometer. UA treatment enhanced platelet aggregation by thrombin, which was concentration-dependent and statistically significant in the tested range ([Fig. 2A left panel](#f2-bt-22-3-254){ref-type="fig"} and [2B gray bars](#f2-bt-22-3-254){ref-type="fig"}). Similar results were obtained with ADP. UA also increased platelet aggregation by 4--10 μM ADP in the same concentration ranges, although the extent of potentiation was weaker than that in thrombin experiments ([Fig. 2A, right panel](#f2-bt-22-3-254){ref-type="fig"}; [2B, black bars](#f2-bt-22-3-254){ref-type="fig"}). Quite comparable effects were observed with OA. OA potentiated the aggregation response of platelets to thrombin or ADP ([Fig. 3](#f3-bt-22-3-254){ref-type="fig"}). Such effect was concentration-dependent in the same range as UA and was statistically significant. In addition to thrombin and ADP, collagen was used to induce aggregation. However, UA and OA had no effect on collagen-induced platelet aggregation (data not shown), suggesting that a platelet effect may vary depending on aggregatory stimuli. To confirm whether the effect on platelet aggregation is related with cytotoxicity, LDH release, a marker of cytotoxicity, was assessed in WP treated with UA or OA at the highest concentration 50 μM. However, significant LDH release was not detected, suggesting that pro-aggregatory activity of them has nothing to do with cytotoxicity ([Fig. 4](#f4-bt-22-3-254){ref-type="fig"}).

Aggregation-enhancing effects of UA and OA were tested in whole blood, which is more complicated, but which is a closer system to the *in vivo* condition than WP. UA or OA was used to pretreat whole blood for 5 min and whole blood aggregation was induced with 0.6--0.7 U/ml thrombin. Similar to WP, whole blood treated with 50 μM UA also exhibited an exaggerated response to thrombin which was statistically significant ([Fig. 5](#f5-bt-22-3-254){ref-type="fig"}). However, the effect of OA was minimal in whole blood. A positive control, dipyridamole effectively and significantly inhibited whole blood aggregation ([Fig. 4 gray bar](#f4-bt-22-3-254){ref-type="fig"}).

As another major player in blood clotting and thrombosis, coagulation factors were tested for their activities in the presence of UA or OA. PT and aPTT represented the activities of the extrinsic pathway and the intrinsic pathway in the coagulation cascade, respectively. Blood plasma was incubated with UA and OA for 5 min, and PT and aPTT were measured. No significant change was detected in PT and aPTT using up to 50 μM UA or OA, indicating little, if any, effect on plasma coagulation ([Table 1](#t1-bt-22-3-254){ref-type="table"}).

DISCUSSION
==========

This study investigated the effect of triterpenoids UA and OA on platelets. UA and OA made platelets susceptible to pro-aggregatory stimuli. Platelets play a primary role in a hemostasis through aggregation. However, primed platelets readily form thrombus and thereby contribute to the development of diverse cardiovascular diseases ([@b23-bt-22-3-254]). It is plausible that UA and OA may be causative factors in cardiovascular diseases by favoring platelet aggregation. Although the specific mechanism is elusive and clinical validation remains to be assessed, it is worth stressing that these compounds need to be used with caution, especially in the population with a predisposition to cardiovascular events.

Studies regarding the effect of UA and OA on the function of platelets have yielded equivocal findings. [@b14-bt-22-3-254] and [@b15-bt-22-3-254] and [@b4-bt-22-3-254] reported antiaggregatory effects of UA and OA, whereas Lee *et al.* (2007) observed aggregation-inducing activity of OA. The half-maximal inhibitory concentration (IC~50~) reported previously was unusually high in the studies reporting aggregation inhibitory effect. [@b4-bt-22-3-254] reported IC~50~ at mM levels and [@b14-bt-22-3-254] and [@b15-bt-22-3-254] reported values at high μM to mM levels. Most of all, it is hard to expect physiological relevancy if the effective concentration is high. Indeed, [@b4-bt-22-3-254] also held the view that the antiplatelet activity of UA or OA was too weak to exert a practical effect. A comparably high concentration was used presently to reproduce previous studies. However, the solubility of UA or OA was too poor to be applied to platelets and such high concentrations were not feasible for measurements using the turbidimetric aggregometer (data not shown). UA or OA is practically insoluble in aqueous solution. Dimethylsulfoxide was used as a vehicle in our study. However, the solubility of UA and OA does not exceed several tens mM, even in organic solvent ([@b13-bt-22-3-254]) and it is not possible to apply them in the mM range to WP considering the influence of organic solvent on platelet activity. In another study, OA supplied at 50 to 200 μM directly induced aggregation of rabbit platelets within 10 min without addition of any agonists ([@b16-bt-22-3-254]). However, such direct aggregation was not observed in this study (data not shown). Instead, OA made platelets sensitive to stimuli. There seems to be no major difference in experimental methods except species difference of platelets source between the present and a previous ([@b16-bt-22-3-254]) study. Lee *et al.* (2007) tested rabbit platelets, while rats were used for this study. Further study will be needed for a full understanding of the discrepancy.

UA and OA were effective at higher than 10 μM in this experiments. There are a limited number of studies reporting blood level of UA and OA. The peak plasma concentration (C~max~) was 3404.6 ± 748.8 ng/ml (= approximately 7.5 μM) in humans given an injection of UA at an average dose of 98 mg/m^2^ body surface area (an average is 1.7 m^2^ for adult males) ([@b36-bt-22-3-254]). In a study using an oral dose of 10 mg/kg bodyweight UA in rats, the C~max~ was found to be 1.10 ± 0.31 μg/ml (= approximately 2.4 μM) ([@b5-bt-22-3-254]). These levels in blood plasma are not quite different from the concentration used in this study, and therefore the effective concentration of UA may be a clinically relevant level. In case of OA, relatively lower levels were detected in blood plasma. The C~max~ was 12.12 ± 6.84 ng/ml (= approximately 0.027 μM) in humans taking a single 40 mg dose of the OA capsule orally ([@b32-bt-22-3-254]). It was 132.0 ± 122.0 ng/ml (= approximately 0.29 μM) in rats orally administered at a dose of 50 mg/kg ([@b12-bt-22-3-254]). Plasma OA levels reported are lower than the concentration used in this study. However, clinical exposure to UA or OA can be more extensive than administered doses in these studies. UA and OA are very widely distributed in food products and herbs. There are a large number of rich sources for them including an apple and Ayurvedic herbs such as Holy Basil. For example, a common spice herb rosemary contains 2.95 g/100 g UA and the content of OA is 3.1 g/100 g dry weight in olive leaves ([@b10-bt-22-3-254]). Such high content in food raises the possibility of longer and extensive exposure to UA or OA, which implies that a daily intake of UA or OA may be larger than doses in kinetic studies described above and thus the plasma concentration can be higher than the reported levels. Taken together, the concentrations of UA and OA in this study are not irrelevant clinically.

Currently, the mechanism how UA and OA contribute to platelet aggregation is elusive. Both UA and OA enhanced aggregation induced by thrombin or ADP, but not by collagen. Thrombin, ADP and collagen have their own distinct ways of activating platelets. The former two stimulate phospholipase Cβ through G protein-coupled receptors protease-activated receptors (PAR) and P2Y receptors respectively, while collagen triggers phospholipase Cγ2 activation via platelet receptor glycoprotein IV and generate downstream signals ([@b24-bt-22-3-254]). Accordingly, UA and OA appear to affect specific signaling pathways rather than to exert non-specific activity, and G protein/phospholipase Cβ-mediated signals by thrombin and ADP receptors might be the targets for UA and OA.

The effects of UA and OA on coagulation were examined by measuring PT and aPTT. However, neither compound affected plasma clotting, suggesting that platelets, rather than clotting factors, are a major target in whole blood and that the hyperaggregation of whole blood is mainly caused by the influence on platelets ([Fig. 4](#f4-bt-22-3-254){ref-type="fig"}). This is consistent with previous studies reporting little or negligible effect of UA or OA ([@b17-bt-22-3-254]; [@b2-bt-22-3-254]), although a conflicting observation was reported ([@b18-bt-22-3-254]).

Whole blood is generally regarded as being more similar to the *in vivo* situation than isolated platelets ([@b21-bt-22-3-254]), although it is hard to interpret the results from whole blood because of the complexity of its composition. In a whole blood study, OA failed to potentiate aggregation unexpectedly, while UA was effective as was in WP experiments ([Fig. 4](#f4-bt-22-3-254){ref-type="fig"}). Ineffectiveness may be ascribed to a rapid metabolism in whole blood or uneven distribution in other cells than platelets and, thus, less exposure to platelets. Another possibility is the insensitivity of whole blood aggregometry. In general, whole blood aggregometry that relies on impedance measurement is less sensitive in detecting microaggregates compared with turbidimetric platelet aggregometer. Although both impedance and optical aggregometry are validated platelet function tests, these two methods do not always produce the same results ([@b9-bt-22-3-254]; [@b6-bt-22-3-254]). Impedance aggregometry is considered a less sensitive technique for detecting mild aggregation compared with optical method because formation of aggregates in the sample will have no effect on the measured impedance unless the aggregates attach to the electrodes, and a small number of attached platelets is unlikely to have a significant impact on the measured impedance of the circuit ([@b11-bt-22-3-254]). Accordingly, aggregation in the whole blood aggregometer indicates the formation of substantial macroaggregates ([@b11-bt-22-3-254]). Therefore, potentiation of platelet aggregation by OA may not be detected in whole blood, even though OA favors the formation of small aggregates. Along with structural similarity, UA and OA have diverse biological activities in common ([@b19-bt-22-3-254]; [@b26-bt-22-3-254]). Therefore, it is not strange that both UA and OA exhibit similar activity on platelet aggregation. However, detailed mechanism underlying such effect may be different each other, as shown in the whole blood experiments.

UA and OA have been generally considered to be safe and beneficial phytochemicals ([@b19-bt-22-3-254]; [@b31-bt-22-3-254]; [@b30-bt-22-3-254]), but the results of our experiments, together with previous reports ([@b17-bt-22-3-254]; [@b16-bt-22-3-254]; [@b2-bt-22-3-254]; [@b22-bt-22-3-254]), raise the question regarding cardiovascular toxicity. The detailed mechanisms have not yet been revealed, nor have the conditions and the reasons for their opposing activities. Further study is warranted to ensure the safe use of UA, OA, and their derivatives.
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![Chemical structures of ursolic acid and oleanolic acid.](bt-22-3-254f1){#f1-bt-22-3-254}

![Effect of ursolic acid (UA) on platelet aggregation. Platelets were incubated with UA for 5 min and aggregation was induced either by 0.06-0.08 U/ml thrombin or 4--10 μM ADP. Representative tracings of UA-treated platelet aggregation are presented in (A). The bar graph in (B) indicates the fold increase in aggregation compared to the control. All values are mean ± standard error (n=4 for thrombin experiment and 7 for ADP experiment). ^\*^ indicates a statistically significant difference from control (*p*\<0.05).](bt-22-3-254f2){#f2-bt-22-3-254}

![Effect of oleanolic acid (OA) on platelet aggregation. Following 5 min treatment of OA, platelet aggregation was induced by 0.06--0.08 U/ml thrombin or 4--10 μM ADP. (A) Representative tracings of OA-treated platelet aggregation. (B) The fold-increase of aggregation compared to the control. All values are mean ± standard error (n=3 for thrombin experiment and 4 for ADP experiment). ^\*^ indicates a statistically significant difference from control (*p*\<0.05).](bt-22-3-254f3){#f3-bt-22-3-254}

![Cytotoxicity of ursolic acid (UA) and oleanolic acid (OA) on platelets. Platelets were treated with 50 μM UA or OA, and the cytotoxicity was assessed by measuring the activity of lactate dehydrogenase (LDH) released. For a positive control, 250 μM menadione was treated to platelets. All values are mean ± standard error (n=3). ^\*^Indicates a statistically significant difference from control (*p*\<0.05).](bt-22-3-254f4){#f4-bt-22-3-254}

![Effect of ursolic acid (UA) and oleanolic acid (OA) on thrombin-induced whole blood aggregation. After treatment with 50 μM UA or OA for 5 min, aggregation of whole blood was initiated by the addition of 0.6--0.7 U/ml thrombin. Dipyridamole (Dip) at 100 μM was used as a negative control. Values are mean ± standard error (n=4). ^\*^Indicates a statistically significant difference from control (*p*\<0.05).](bt-22-3-254f5){#f5-bt-22-3-254}

###### 

Effect of ursolic acid (UA) and oleanolic acid (OA) on plasma coagulation

             PT                                                         aPTT
  ---------- ---------------------------------------------------------- --------------------------------------------------------
  Control    13.7 ± 0.2                                                 20.3 ± 0.7
  UA 5 μM    13.9 ± 0.3                                                 18.7 ± 0.6
  UA 25 μM   14.0 ± 0.3                                                 19.8 ± 0.7
  UA 50 μM   13.8 ± 0.3                                                 20.2 ± 0.9
  OA 5 μM    13.8 ± 0.2                                                 19.6 ± 0.3
  OA 25 μM   13.8 ± 0.3                                                 19.5 ± 0.8
  OA 50 μM   14.0 ± 0.0                                                 19.8 ± 0.9
  Heparin    27.1 ± 1.8[^\*^](#tfn2-bt-22-3-254){ref-type="table-fn"}   \> 120.0[^\*^](#tfn2-bt-22-3-254){ref-type="table-fn"}

Values are expressed as mean ± standard error (n=3). Heparin (0.4 IU/μl) was used as a negative control. PT: prothrombin time, aPTT: activated partial thromboplastin time.

Indicates a statistically significant difference from control (*p*\<0.05).
